UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
FOUNDATION MEDICINE, INC.
(Name of Subject Company)
FOUNDATION MEDICINE, INC.
(Name of Person Filing Statement)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
350465100
(CUSIP Number of Class of Securities)
Michael Pellini, M.D.
President and Chief Executive Officer
Foundation Medicine, Inc.
150 Second Street
Cambridge, MA 02141
(617) 481-2200
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)
With copies to:
Stuart M. Cable, Esq.
Lisa R. Haddad, Esq.
Kingsley L. Taft, Esq.
Goodwin Procter LLP
Exchange Place
Boston, MA 02109
(617) 570-1000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)
x | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Item 1.01 of the amendment to the Current Report on Form 8-K filed by Foundation Medicine, Inc. on February 2, 2015 (including all exhibits attached thereto) is incorporated herein by reference.